Navigation Links
Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro)
Date:11/13/2007

MOORESVILLE, N.C., Nov. 13 /PRNewswire-FirstCall/ -- Anpath Group, Inc. (OTC Bulletin Board: ANPG), reported today that its wholly-owned subsidiary, EnviroSystems, Inc. (ESI) announced the selection of its disinfectant, EnviroTru(TM) for use by the Washington Metropolitan Area Transit Authority (Metro).

EnviroTru(TM) is a multi-purpose disinfectant and deodorizing cleaner effective against numerous organisms, and also meets EPA requirements for Toxicity Category IV (no harmful dermal, ocular, inhalation or ingestion effects). ESI reported that Metro recently placed an initial order for more than 600 gallons of the disinfectant.

"It is especially gratifying for our product/technology to be chosen by the transit system serving our Nation's Capital", stated ESI President and CEO, J. Lloyd Breedlove. Mr. Breedlove continued, "EnviroTru(TM) is ideally suited for use in a transit system environment. As a result of its biocidal efficacy combined with its favorable materials compatibility and environmental profile EnviroTru(TM) is a natural choice for heavy traffic areas".

Metro is the tri-jurisdictional government agency authorized by Congress to operate the transit service in the Washington, DC metropolitan area, including the Metrorail and Metrobus; totaling more than 11,000 rail cars, buses and special means transport vehicles. Metro is also part of the public- private partnership that operates the DC Circulator bus system. Polly Hanson, Assistant General Manager of Safety, Security and Emergency Management with Metro stated, "We are pleased to have identified and selected a product with the characteristics of EnviroTru(TM). It is important that we make every effort to protect our customers and employees against the spread of infectious diseases without exposing them to harmful chemicals, while also taking into account our equipment and the environment in general."

ESI stated that in addition to daily application of EnviroTru(TM) on high hand contact areas such as door handles, hand rails, fare card machine buttons, etc., in the event of a pandemic flu or other infectious disease outbreak Metro is prepared to use EnviroTru(TM) with the Foster-Miller, Inc. Electrostatic Charged Aerosol Decontamination System (ECADS) (http://www.fostermiller.com/ecadsproduct.htm) to spray rail cars, buses and other vehicles daily. ESI worked with Foster-Miller, Inc. to validate the use of its disinfectant with ECADS.

According to Foster-Miller, Inc. representative, Rick Lusignea, "Metro purchased 17 high efficiency air assisted ECADS sprayers from Foster-Miller to dispense EnviroTru(TM)". Mr. Lusignea explained, "The ECAD decontamination and remediation system disperses fine electrically charged droplets of decontaminant into the air. Because of the static charge imparted to aerosol particles, ECADS provides a much higher amount of disinfectant on surfaces than conventional air assisted spray systems, approximately 60% of the total disinfectant dispensed on the surface for the ECADS sprayer, versus less than 15% for conventional sprayers. We think the combination of our ECADS devices and the ESI disinfectant formulation is an extremely strong weapon against disease for Metro."

About Anpath Group, Incorporated:

Anpath Group, Inc., through its wholly-owned subsidiary EnviroSystems, Inc., produces cleaning and disinfecting products that it believes will help prevent the spread of infectious microorganisms while minimizing the harmful effects to people, equipment or the environment.

EnviroSystems, Inc. is focused on safe infection prevention technologies that the company believes will position the company in the forefront of the industry at a time when there is rapidly growing awareness of the critical need to prevent biological risks - both natural and man-made.

Forward Looking Statements:

This release contains forward-looking statements, which reflect expectation or belief by Anpath Group, Inc. concerning future events that involve risks and uncertainties. Anpath Group can give no assurance that the expectations reflected in forward looking statements will prove correct and various factors could cause results to differ materially from Anpath Group expectations, including, but not limited to EPA registration of the Company's products, the Company's ability to carry out its business plan, successful development and commercial acceptance of its products, ability to fund development of its technology, the risk that products may not result from development activities, protection of its intellectual property, need for regulatory approvals, and other factors discussed in periodic Anpath Group, Inc. filings with the Securities and Exchange Commission. Forward-looking statements are qualified in their entirety by the above cautionary statement. Anpath Group assumes no duty to update its outlook or other forward-looking statements as of any future date.


'/>"/>
SOURCE Anpath Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 ... platform, the first non-viral gene expression technology that enables ... the eye to address a wide range of ophthalmic ... Medicines and Healthcare products Regulatory Agency (MHRA) to advance ... ...
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, Chile, ... their offering. ... Latin American pharmaceutical contract manufacturing services market is anticipated to ... registration cost in Latin American countries and continuous economic growth ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the highest market ... segment is likely to create absolute $ opportunity of a ... By the end of 2027, Cardiology Devices segment is projected ... expanding at a CAGR of 18.4% over the forecast period. ... reprocessed medical devices market in terms of revenue ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... ... Dudnyk has announced the launch of its new brand identity, called The ... specialty and orphan brands can only be achieved when the needs and beliefs of ... at the heart of a true partnership between our agency and our clients to ...
(Date:4/21/2017)... ... 2017 , ... The VIA Agency , a full-service ... Theravent, Inc. , the makers of a revolutionary new device clinically proven to ... working to expand distribution in anticipation of a national launch. VIA will be ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... campaign, AWARE: A Week of Addiction and Recovery Education, from April 24 to ... and preventing substance use disorders. , The mission of AWARE is to ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... the much anticipated Regional Primary Care Spring Symposium on April 1, 2017 in ... medical community, offering physicians and healthcare providers an opportunity to learn about cutting ...
(Date:4/21/2017)... ... , ... Providing for loved ones before one’s passing is of paramount importance. ... begin. “Now more than ever there are some questions that are far too critical ... said attorney Lisa Edgar Dickman, founder of the Law Offices of Lisa Edgar Dickman. ...
Breaking Medicine News(10 mins):